TY - JOUR
T1 - Frontline imatinib treatment of chronic myeloid leukemia
T2 - No impact of age on outcome, a survey by the GIMEMA CML working party
AU - Gugliotta, Gabriele
AU - Castagnetti, Fausto
AU - Palandri, Francesca
AU - Breccia, Massimo
AU - Intermesoli, Tamara
AU - Capucci, Adele
AU - Martino, Bruno
AU - Pregno, Patrizia
AU - Rupoli, Serena
AU - Ferrero, Dario
AU - Gherlinzoni, Filippo
AU - Montefusco, Enrico
AU - Bocchia, Monica
AU - Tiribelli, Mario
AU - Pierri, Ivana
AU - Grifoni, Federica
AU - Marzocchi, Giulia
AU - Amabile, Marilina
AU - Testoni, Nicoletta
AU - Martinelli, Giovanni
AU - Alimena, Giuliana
AU - Pane, Fabrizio
AU - Saglio, Giuseppe
AU - Baccarani, Michele
AU - Rosti, Gianantonio
PY - 2011/5/26
Y1 - 2011/5/26
N2 - The median age of chronic myeloid leukemia (CML) patients is - 60 years, and age is still considered an important prognostic factor, included in Sokal and EURO risk scores. However, few data are available about the long-term outcome of older patients treated with imatinib (IM) frontline. We analyzed the relationship between age and outcome in 559 early chronic-phase CML patients enrolled in 3 prospective clinical trials of Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party, treated frontline with IM, with a median follow-up of 60 months. There were 115 older patients (≥ 65 years; 21%). The complete cytogenetic and major molecular response rates were similar in the 2 age groups. In older patients, event-free survival (55% vs 67%), failure-free survival (78% vs 92%), progression-free survival (62% vs 78%), and overall survival (75% vs 89%) were significantly inferior (all P <.01) because of a higher proportion of deaths that occurred in complete hematologic response, therefore unrelated to CML progression (15% vs 3%, P <.0001). The outcome was similar once those deaths were censored. These data show that response to IM was not affected by age and that the mortality rate linked to CML is similar in both age groups. This trial was registered at www. clinicaltrials.gov as #NCT00514488 and #NCT00510926.
AB - The median age of chronic myeloid leukemia (CML) patients is - 60 years, and age is still considered an important prognostic factor, included in Sokal and EURO risk scores. However, few data are available about the long-term outcome of older patients treated with imatinib (IM) frontline. We analyzed the relationship between age and outcome in 559 early chronic-phase CML patients enrolled in 3 prospective clinical trials of Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party, treated frontline with IM, with a median follow-up of 60 months. There were 115 older patients (≥ 65 years; 21%). The complete cytogenetic and major molecular response rates were similar in the 2 age groups. In older patients, event-free survival (55% vs 67%), failure-free survival (78% vs 92%), progression-free survival (62% vs 78%), and overall survival (75% vs 89%) were significantly inferior (all P <.01) because of a higher proportion of deaths that occurred in complete hematologic response, therefore unrelated to CML progression (15% vs 3%, P <.0001). The outcome was similar once those deaths were censored. These data show that response to IM was not affected by age and that the mortality rate linked to CML is similar in both age groups. This trial was registered at www. clinicaltrials.gov as #NCT00514488 and #NCT00510926.
UR - http://www.scopus.com/inward/record.url?scp=79957588158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957588158&partnerID=8YFLogxK
U2 - 10.1182/blood-2010-12-324228
DO - 10.1182/blood-2010-12-324228
M3 - Article
C2 - 21450900
AN - SCOPUS:79957588158
VL - 117
SP - 5591
EP - 5599
JO - Blood
JF - Blood
SN - 0006-4971
IS - 21
ER -